|
1
|
Liu HT, Zhang S, Liu Y, Ma J, Chen W, Yin
T, Li TB, Liang B and Tao L: Knockdown of HSP110 attenuates
hypoxia-induced pulmonary hypertension in mice through suppression
of YAP/TAZ-TEAD4 pathway. Respir Res. 23(209)2022.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Huang S, Qiu J, Wang A, Ma Y, Wang P, Ding
D, Qiu L, Li S, Liu M, Zhang J, et al: Burden of pulmonary arterial
hypertension in Asia from 1990 to 2021: Findings from Global burden
of disease study 2021. Chin Med J (Engl). 138:1324–1333.
2025.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Mocumbi A, Humbert M, Saxena A, Jing ZC,
Sliwa K, Thienemann F, Archer SL and Stewart S: Pulmonary
hypertension. Nat Rev Dis Primers. 10(1)2024.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Huang H, Hu C, Zhang R, Xu H, Cao M and Fu
Y: Global burden of pulmonary arterial hypertension and associated
heart failure: Global burden of disease 2021 analysis. JACC Heart
Fail. 13(102385)2025.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Farber HW, Miller DP, Poms AD, Badesch DB,
Frost AE, Muros-Le Rouzic E, Romero AJ, Benton WW, Elliott CG,
McGoon MD and Benza RL: Five-year outcomes of patients enrolled in
the REVEAL registry. Chest. 148:1043–1054. 2015.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Deng Y, Wu W, Guo S, Chen Y, Liu C, Gao X
and Wei B: Altered mTOR and Beclin-1 mediated autophagic activation
during right ventricular remodeling in monocrotaline-induced
pulmonary hypertension. Respir Res. 18(53)2017.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Boucherat O, Yokokawa T, Krishna V,
Kalyana-Sundaram S, Martineau S, Breuils-Bonnet S, Azhar N, Bonilla
F, Gutstein D, Potus F, et al: Identification of LTBP-2 as a plasma
biomarker for right ventricular dysfunction in human pulmonary
arterial hypertension. Nat Cardiovasc Res. 1:748–760.
2022.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Amaki M, Nakatani S, Kanzaki H, Kyotani S,
Nakanishi N, Shigemasa C, Hisatome I and Kitakaze M: Usefulness of
three-dimensional echocardiography in assessing right ventricular
function in patients with primary pulmonary hypertension. Hypertens
Res. 32:419–422. 2009.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Vonk-Noordegraaf A, Haddad F, Chin KM,
Forfia PR, Kawut SM, Lumens J, Naeije R, Newman J, Oudiz RJ,
Provencher S, et al: Right heart adaptation to pulmonary arterial
hypertension: Physiology and pathobiology. J Am Coll Cardiol. 62
(25 Suppl):D22–D33. 2013.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Weber KT and Brilla CG: Pathological
hypertrophy and cardiac interstitium. Fibrosis and
renin-angiotensin-aldosterone system. Circulation. 83:1849–1865.
1991.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Lazzeroni D, Rimoldi O and Camici PG: From
left ventricular hypertrophy to dysfunction and failure. Circ J.
80:555–564. 2016.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Xiao F, Li HL, Wang JR, Wu HM, Cai YQ,
Wang JW, Che H, Li G, Xia ZY, Xie YB and Wang S: Research progress
on programmed cell death of cardiomyocytes in pressure-overload
hypertrophic cardiomyopathy. Apoptosis. 30:2191–2224.
2025.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Xin G, Xu-Yong L, Shan H, Gang W, Zhen C,
Ji-Jun L, Ping Y and Man-Hua C: SH2B1 protects cardiomyocytes from
ischemia/reperfusion injury via the activation of the PI3K/AKT
pathway. Int Immunopharmacol. 83(105910)2020.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Meco M, Giustiniano E, Nisi F, Zulli P and
Agosteo E: MAPK, PI3K/Akt Pathways, and GSK-3β Activity in severe
acute heart failure in intensive care patients: An updated review.
J Cardiovasc Dev Dis. 12(266)2025.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Cheng Y, Shen A, Wu X, Shen Z, Chen X, Li
J, Liu L, Lin X, Wu M, Chen Y, et al: Qingda granule attenuates
angiotensin II-induced cardiac hypertrophy and apoptosis and
modulates the PI3K/AKT pathway. Biomed Pharmacother.
133(111022)2021.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Chen L, Chen LJ, Shen HW, Hsu C, Zeng JH,
Li JH, Liu JL, Yang JZ, Liu Y, Li XW, et al: Inhibition of HIF-2α
expression in cardiomyocytes attenuates PCB126-induced
cardiotoxicity associated with decreased apoptosis through the
PI3K/Akt and p53 signaling pathways. Ecotoxicol Environ Saf.
286(117185)2024.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Zhao Q, Zhao X, Zhang X, Cong R, Chen X,
Dong D and Sun M: Mechanisms of aerobic exercise on
doxorubicin-induced cardiomyocyte apoptosis: Based on AMPK/PI3K/AKT
signalling pathway. Life Sci. 376(123731)2025.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Goncharova EA, Ammit AJ, Irani C, Carroll
RG, Eszterhas AJ, Panettieri RA and Krymskaya VP: PI3K is required
for proliferation and migration of human pulmonary vascular smooth
muscle cells. Am J Physiol Lung Cell Mol Physiol. 283:L354–L363.
2002.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Garat CV, Crossno JT Jr, Sullivan TM,
Reusch JE and Klemm DJ: Inhibition of phosphatidylinositol
3-kinase/Akt signaling attenuates hypoxia-induced pulmonary artery
remodeling and suppresses CREB depletion in arterial smooth muscle
cells. J Cardiovasc Pharmacol. 62:539–548. 2013.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Kilkenny C, Browne W, Cuthill IC, Emerson
M and Altman DG: Animal research: Reporting in vivo experiments:
The ARRIVE guidelines. Br J Pharmacol. 160:1577–1579.
2010.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Wang Y, Fan Y, Song Y, Han X, Fu M, Wang
J, Cui X, Cao J, Chen L, Hu K, et al: Angiotensin II induces
apoptosis of cardiac microvascular endothelial cells via regulating
PTP1B/PI3K/Akt pathway. In Vitro Cell Dev Biol Anim. 55:801–811.
2019.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) Method. Methods. 25:402–408.
2001.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Qin W, Cao L and Massey IY: Role of
PI3K/Akt signaling pathway in cardiac fibrosis. Mol Cell Biochem.
476:4045–4059. 2021.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Xiao F, Li HL, Yang B, Che H, Xu F, Li G,
Zhou CH and Wang S: Disulfidptosis: A new type of cell death.
Apoptosis. 29:1309–1329. 2024.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Scholzen T and Gerdes J: The Ki-67
protein: From the known and the unknown. J Cell Physiol.
182:311–22. 2000.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Kar A, Gupta S, Matilal A and Sarkar S:
Tissue engineering with targeted delivery of nanotized S-nitrosyl
mutant of NEMO ameliorates myocardial infarction. Nanomedicine
(Lond). 20:1085–1099. 2025.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Han Z, Zhang X, Liu C, Lu M, Wang J, Nie Y
and Zhang H: Analysis of long noncoding RNAs expression profiles in
the human cardiac fibroblasts with cardiac fibrosis. Biochem
Biophys Res Commun. 660:73–81. 2023.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Franco V, Ryan JJ and McLaughlin VV:
Pulmonary hypertension in women. Heart Fail Clin. 15:137–145.
2019.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Yogeswaran A, Mamazhakypov A, Schermuly RT
and Weiß A: Right ventricular failure in pulmonary hypertension:
Recent insights from experimental models. Herz. 48:285–290.
2023.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Namazi M, Eftekhar SP, Mosaed R,
Shiralizadeh Dini S and Hazrati E: Pulmonary hypertension and right
ventricle: A pathophysiological insight. Clin Med Insights Cardiol.
18(11795468241274744)2024.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Waddingham MT, Tsuchimochi H, Sonobe T,
Sequeira V, Nayeem MJ, Shirai M, Pearson JT and Ogo T: The
selective serotonin reuptake inhibitor paroxetine improves right
ventricular systolic function in experimental pulmonary
hypertension. J Mol Cell Cardiol Plus. 8(100072)2024.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Ma ZG, Yuan YP, Fan D, Zhang X, Teng T,
Song P, Kong CY, Hu C, Wei WY and Tang QZ: IRX2 regulates
angiotensin II-induced cardiac fibrosis by transcriptionally
activating EGR1 in male mice. Nat Commun. 14(4967)2023.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Mandell E, Kinsella JP and Abman SH:
Persistent pulmonary hypertension of the newborn. Pediatr Pulmonol.
56:661–669. 2021.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Mukherjee D and Konduri GG: Pediatric
pulmonary hypertension: Definitions, mechanisms, diagnosis, and
treatment. Compr Physiol. 11:2135–2190. 2021.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Hou C, Chen J, Zhao Y, Niu Y, Lin S, Chen
S, Zong Y, Sun X, Xie L and Xiao T: The emerging role of fatty acid
synthase in hypoxia-induced pulmonary hypertensive mouse energy
metabolism. Oxid Med Cell Longev. 2021(9990794)2021.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Hou B, Su S, Ji L, Huayu M, Yang N, Yang
Z, Li Z and Lu D: Luteolin alleviates right ventricular hypertrophy
in high altitude pulmonary hypertension rats by regulating
PI3K/AKT/mTOR signalling pathway. Eur J Pharmacol.
1003(177898)2025.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Noorabadi P, Shahabi Rabori V, Jamali S,
Jafari N and Saberiyan M: An overview on cardiac regeneration
revolution: Exploring the promise of stem cell therapies. Mol Biol
Rep. 52(511)2025.PubMed/NCBI View Article : Google Scholar
|
|
38
|
Park E and Safdar Z: Pulmonary
hypertension in women. Methodist Debakey Cardiovasc J. 20:70–80.
2024.PubMed/NCBI View Article : Google Scholar
|
|
39
|
Wiese CB, Avetisyan R and Reue K: The
impact of chromosomal sex on cardiometabolic health and disease.
Trends Endocrinol Metab. 34:652–665. 2023.PubMed/NCBI View Article : Google Scholar
|
|
40
|
Dignam JP, Sharma S, Stasinopoulos I and
MacLean MR: Pulmonary arterial hypertension: Sex matters. Br J
Pharmacol. 181:938–966. 2024.PubMed/NCBI View Article : Google Scholar
|
|
41
|
Reue K and Wiese CB: Illuminating the
mechanisms underlying sex differences in cardiovascular disease.
Circ Res. 130:1747–1762. 2022.PubMed/NCBI View Article : Google Scholar
|
|
42
|
Ventetuolo CE and Sherman-Roe AE: Sex
differences in pulmonary (arterial) hypertension: does it matter?
Curr Opin Pulm Med. 31:411–428. 2025.PubMed/NCBI View Article : Google Scholar
|
|
43
|
Savineau JP, Marthan R and Dumas de la
Roque E: Role of DHEA in cardiovascular diseases. Biochem
Pharmacol. 85:718–726. 2013.PubMed/NCBI View Article : Google Scholar
|
|
44
|
Dumas de la Roque E, Savineau JP and
Bonnet S: Dehydroepiandrosterone: A new treatment for vascular
remodeling diseases including pulmonary arterial hypertension.
Pharmacol Ther. 126:186–199. 2010.PubMed/NCBI View Article : Google Scholar
|
|
45
|
Yuan P, Wu WH, Gao L, Zheng ZQ, Liu D, Mei
HY, Zhang ZL and Jing ZC: Oestradiol ameliorates monocrotaline
pulmonary hypertension via NO, prostacyclin and endothelin-1
pathways. Eur Respir J. 41:1116–1125. 2013.PubMed/NCBI View Article : Google Scholar
|
|
46
|
Al-Qazazi R, Lima PDA, Prisco SZ, Potus F,
Dasgupta A, Chen KH, Tian L, Bentley RET, Mewburn J, Martin AY, et
al: Macrophage- NLRP3 activation promotes right ventricle failure
in pulmonary arterial hypertension. Am J Respir Crit Care Med.
206:608–624. 2022.PubMed/NCBI View Article : Google Scholar
|
|
47
|
Latimer K, Layne1 M and Payne M: Pulmonary
hypertension. Am Fam Physician. 110:183–191. 2024.PubMed/NCBI
|
